Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Speaking from the 23rd congress of the European Hematology Association (EHA) 2018 press briefing, held in Stockholm, Sweden, Dr Jesús Berdeja of the Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN, gives an update on bb2121, a promising therapy for patients with heavily pre-treated relapsed/refractory multiple myeloma (MM).
We use cookies to provide the best experience on our website. We also use third party cookies to collect analytical data and better improve our marketing strategies. If you continue to use this site you are consenting to the use of these cookies. For more information view our Cookie Policy.